Background: Facial rejuvenation is becoming more and more popular, particularly among middle-aged persons. There are currently many techniques for improving the aforementioned situations, but each has its drawbacks. Our study aimed to discuss the treatment effect of a composited technique for reversing both lower eyelid and midface aging.

Methods: The patient's face was designed and measured before surgery. During surgery, a traditional lower blepharoplasty incision was made. The layer between the orbital septum and the orbicularis oculi muscle was separated to approximately 4-5 mm below the infraorbital, then the orbital septum and orbicularis retaining ligament were found to be released. A self-made suspension curving needle subconsciously passed through the brim of the superficial cheek fat pad via the "U-type" path and raised them to the proper location. Then sutured them to the infraorbital rim periosteum, as well as the suborbicularis oculi fat (SOOF) and the orbital septum fat. Secured the outside canthus to keep the lower lid position stable.

Results: From February 2020 to November 2022, 106 patients underwent the new surgical procedure and were successfully followed up for 20 ± 6.5 months postoperatively. The mean GAIS score was 2.42 ± 0.78, patient satisfaction rate was 95%. All of the Barton grades were decreased. The nasal base level suspension points were elevated to a level of 5 ± 2 mm. 3D measurement data revealed significant improvements.

Conclusions: The composited technique is a safe and effective way to reverse the aging of the lower eyelid and midface.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626286PMC
http://dx.doi.org/10.1111/srt.13511DOI Listing

Publication Analysis

Top Keywords

composited technique
12
lower eyelid
12
orbital septum
12
technique reversing
8
reversing lower
8
eyelid midface
8
septum orbicularis
8
lower
5
u-type soft
4
soft tissue
4

Similar Publications

Background: Dementia, a growing health crisis, disproportionally affects persons from racial/ethnic backgrounds and individuals with comorbidities. Latelife change in cognition is complex and nonlinear, as well as differential for these individuals. These individuals are also largely underrepresented in clinical trials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Longeveron Inc., Miami, FL, USA.

Background: Lomecel-B is a novel cell-based therapy with potential to demonstrate clinical benefit on Alzheimer's disease (AD) and its progression. Here we present the results of a phase 2a proof-of-concept trial (n = 49) to further define the potential of Lomecel-B in patients with mild AD dementia.

Methods: This double-blind, randomized, placebo-controlled 45-week trial (ClinicalTrials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Anavex Life Sciences, New York, NY, USA.

Background: In AD trials, the treatment effect is typically evaluated by estimating the absolute difference in change from baseline to the end-of-study visit (e.g., 18 months) between treatment arms using the MMRM model.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Pentara, Salt Lake CIty, UT, USA.

Background: Clinical assessments utilized in trials to measure progression in sporadic Alzheimer's disease (SAD) such as the MMSE, ADAS-Cog, CDR-SB and ADCS-ADL are well established. Distinct assessments are utilized for Down Syndrome-related Alzheimer's disease (DSAD). Although these assessments are less well established, they probe comparable domains of cognition and function.

View Article and Find Full Text PDF

Background: Our previous work has found that sexual and gender minority (SGM) or LGBTQIA+ caregivers of people living with Alzheimer's disease and related dementias (ADRD) experience higher levels of stigma, depressive symptoms, and stress than non-SGM caregivers and that these outcomes are associated with experiences of microaggressions related to their SGM identities. Guided by the Health Equity Promotion Model, we sought to explore the impact of the environmental context on psychosocial outcomes among SGM caregivers of people living with ADRD.

Methods: Data from a cross-sectional online survey using a non-probabilistic sample of SGM caregivers of people with ADRD recruited via social media (n = 284) were combined with publicly available data reporting composite equity climate index scores across five domains: legal/non-discrimination protections, youth/family support, political/religious attitudes, health access/safety, and work environment/employment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!